Cagrilintide+Semaglutide is a research blend pairing a long-acting amylin analog (Cagrilintide) with a GLP-1 receptor agonist (Semaglutide). Studied under the research designation CagriSema, the combination engages two distinct metabolic signaling systems, the amylin/calcitonin receptors and the GLP-1 receptor, allowing researchers to examine parallel and potentially complementary pathway activity. Puritide Research supplies this blend as a high-purity, research-use-only material, synthesized for in vitro and animal-model work and backed by third-party-verified certificates of analysis so your data rests on consistent, documented quality.
Available Sizes
- ›Cagrilintide+Semaglutide 5+5 mg Vial
Product Specifications
- Application
- Combined amylin + incretin signaling research (amylin analog / GLP-1 agonist)
- Appearance
- Solid, white lyophilized powder in a sealed glass vial
- Chemical Formula
- Cagrilintide: C194H312N54O59S2; Semaglutide: C187H291N45O59
- CAS Number
- Cagrilintide: 1415456-99-3; Semaglutide: 910463-68-2
- Molecular Weight
- Cagrilintide: ~4409.01 g/mol; Semaglutide: ~4113.64 g/mol
- Synonyms
- CagriSema, Cagrilintide/Semaglutide blend, amylin analog + GLP-1 agonist stack, AM833 + semaglutide
- Storage
- Store at ≤25°C, sealed, away from heat, light, and moisture. For extended storage, keep lyophilized and refrigerated or frozen.
What Is Cagrilintide+Semaglutide?
Cagrilintide+Semaglutide is a co-formulated blend of two research peptides. Cagrilintide is a long-acting, acylated amylin analog that engages the amylin and calcitonin receptor systems. Semaglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist.
The two components are studied together, under the research designation CagriSema, because amylinergic and incretin signaling operate through separate receptor systems that both influence metabolic pathways. In experimental models this pairing is used to investigate how the two systems behave when engaged in parallel, and how combined signaling compares with either pathway alone.
Present understanding derives from in vitro assays, animal models, and clinical research. Findings should be interpreted within their experimental context and not treated as established clinical outcomes. Puritide Research supplies this blend strictly for laboratory use; it is not approved for human or veterinary application.
Cagrilintide+Semaglutide Mechanism of Action (Research Only)
This blend is studied for its engagement of two distinct metabolic signaling systems, the amylin/calcitonin receptors (via Cagrilintide) and the GLP-1 receptor (via Semaglutide). The mechanisms below reflect observations from biochemical assays, cell-culture studies, and animal models, and should be read strictly in a research context.
Amylinergic Signaling (Cagrilintide)
Cagrilintide is investigated as a non-selective agonist across amylin receptor subtypes and the calcitonin receptor. Its acylation-based albumin binding is associated with prolonged persistence and sustained receptor engagement in vitro, providing a model for amylinergic signaling that native amylin cannot sustain.
Incretin Signaling & Convergent Pathways (Semaglutide)
Semaglutide is investigated as a GLP-1 receptor agonist. In experimental systems, GLP-1 receptor engagement is associated with cAMP-dependent signaling in relevant cell populations. Semaglutide's acylation likewise supports extended in vitro persistence.
When the two components are studied together, the research interest is convergent metabolic signaling: parallel engagement of the amylin and GLP-1 receptor systems has been reported in combination studies to produce metabolic effects exceeding either agonist alone. This blend serves as a research tool for examining that proposed interaction under controlled conditions.
Cagrilintide+Semaglutide Research Applications
This blend is investigated across preclinical and translational studies as a dual amylin–incretin system for exploring combined metabolic signaling. The observations below derive from biochemical studies, cell-based assays, and animal models, and should be interpreted within their respective settings.
Combined Amylin–Incretin Signaling
A primary application is investigating how simultaneous amylin-receptor and GLP-1-receptor engagement influences metabolic signaling in model systems. Researchers use the blend to examine whether combined stimulation produces responses distinct from single-system agonism.
The blend is also used in comparative research contrasting amylin analogs, GLP-1 agonists, and their combination, characterizing differences in signaling behavior and pathway interaction without establishing physiological outcomes.
Energy-Balance & Translational Models
Researchers use this blend to study energy-balance signaling networks and the interaction of amylinergic and incretin pathways in animal models, bridging mechanistic findings with broader investigations of combination peptide pharmacology. These studies aim to improve understanding of receptor-mediated regulation rather than to establish physiological or therapeutic effects.
Comparison
| Parameter | Cagrilintide | Semaglutide |
|---|
| Molecular classification | Synthetic long-acting amylin analog | Synthetic GLP-1 receptor agonist |
| Primary receptor targets | Amylin receptors (AMY) & calcitonin receptor (CTR) | GLP-1 receptor (GLP-1R) |
| Native hormone basis | Amylin | Glucagon-like peptide-1 |
| Role in blend | Amylinergic signaling arm | Incretin signaling arm |
| Duration strategy | Acylation / albumin binding | Acylation / albumin binding |
Laboratory Safety & Handling (Research Use Only)
Cagrilintide+Semaglutide is a synthetic, lyophilized research peptide blend for laboratory investigation only. It should be handled by qualified personnel in controlled environments, in accordance with institutional policies, laboratory safety procedures, and applicable regulations. As a research material, laboratories should implement practices that prioritize material integrity, traceability, and reproducibility.
Handling & Storage Guidelines
Follow institutional SOPs, chemical hygiene plans, and approved protocols; wear appropriate PPE (lab coat, gloves, eye protection); and use engineering controls where required. Record lot numbers, storage conditions, and handling activities, and retain Certificates of Analysis and batch documentation to support traceability and audit readiness.
Store material under the conditions specified in product documentation, protected from excessive heat, moisture, and direct light. Reconstituted peptide should be kept refrigerated and used within the timeframe indicated by your protocol. Consistent handling and documentation support reliable, reproducible outcomes.
Certificate of Analysis & Quality Assurance
Each Cagrilintide+Semaglutide batch ships with a third-party-verified Certificate of Analysis, providing transparent, research-grade quality control. The CoA includes a purity assessment (HPLC / reverse-phase chromatography), mass-spectrometry identity confirmation of both peptide components, and lot number, testing date, and method documentation.
Researchers may request sample CoAs (PDF) ahead of purchase to confirm testing parameters, analytical methods, and batch consistency, and are encouraged to perform independent verification.
Research Use Only
